Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,773
-5.18%
|
$152,411
$7.65 P/Share
|
|
Dec 22
2025
|
Charles K Gayer President and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
74,233
+2.55%
|
$296,932
$4.59 P/Share
|
|
Dec 19
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,902
-3.86%
|
$118,314
$7.41 P/Share
|
|
Dec 19
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
61,793
-4.46%
|
$432,551
$7.41 P/Share
|
|
Dec 19
2025
|
Charles K Gayer President and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,477
-1.29%
|
$80,339
$7.41 P/Share
|
|
Dec 18
2025
|
Jon P Stonehouse Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
20,000
+20.0%
|
-
|
|
Dec 18
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-1.42%
|
-
|
|
Dec 17
2025
|
Charles K Gayer President and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
471,000
+34.61%
|
-
|
|
Dec 17
2025
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
121,700
+21.77%
|
-
|
|
Dec 17
2025
|
Babar Ghias Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
121,700
+31.17%
|
-
|
|
Dec 15
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
21,210
-6.3%
|
$148,470
$7.65 P/Share
|
|
Dec 12
2025
|
Charles K Gayer President and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,181
-1.92%
|
$57,267
$7.57 P/Share
|
|
Dec 12
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,540
-2.47%
|
$59,780
$7.57 P/Share
|
|
Dec 12
2025
|
Jon P Stonehouse Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,368
-1.91%
|
$191,576
$7.57 P/Share
|
|
Dec 03
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
19,770
-5.41%
|
$138,390
$7.65 P/Share
|
|
Dec 02
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
50,906
-12.23%
|
$356,342
$7.21 P/Share
|
|
Dec 01
2025
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
91,004
-17.94%
|
$637,028
$7.1 P/Share
|
|
Dec 01
2025
|
Alane P Barnes Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,004
+15.21%
|
$273,012
$3.22 P/Share
|
|
Nov 28
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,566
+8.16%
|
$10,962
$7.18 P/Share
|
|
Nov 28
2025
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
783
+1.84%
|
$5,481
$7.18 P/Share
|
|
Nov 28
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
783
+0.85%
|
$5,481
$7.18 P/Share
|
|
Nov 13
2025
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
9,600
-23.86%
|
$67,200
$7.14 P/Share
|
|
Aug 29
2025
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
676
+1.62%
|
$5,408
$8.31 P/Share
|
|
Aug 29
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
676
+0.74%
|
$5,408
$8.31 P/Share
|
|
Aug 29
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,353
+7.77%
|
$10,824
$8.31 P/Share
|
|
Aug 13
2025
|
Theresa Heggie Director |
SELL
Open market or private sale
|
Direct |
70,000
-51.72%
|
$560,000
$8.51 P/Share
|
|
Aug 13
2025
|
Theresa Heggie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
70,000
+23.37%
|
$280,000
$4.16 P/Share
|
|
Jul 24
2025
|
Babar Ghias Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
147,000
+50.0%
|
-
|
|
Jun 12
2025
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+16.06%
|
-
|
|
Jun 12
2025
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+11.2%
|
-
|
|
Jun 12
2025
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+16.28%
|
-
|
|
Jun 12
2025
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+23.66%
|
-
|
|
Jun 12
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+12.22%
|
-
|
|
Jun 12
2025
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+23.7%
|
-
|
|
Jun 12
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+45.96%
|
-
|
|
Jun 12
2025
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+33.34%
|
-
|
|
May 30
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
333
+13.15%
|
$3,330
$10.75 P/Share
|
|
May 30
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
523
+0.67%
|
$5,230
$10.75 P/Share
|
|
May 02
2025
|
Steven Frank Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,866
+50.0%
|
-
|
|
Mar 31
2025
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,525
-1.96%
|
$52,675
$7.5 P/Share
|
|
Feb 28
2025
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
653
+0.84%
|
$5,224
$8.61 P/Share
|
|
Dec 20
2024
|
Jon P Stonehouse Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
20,000
+25.0%
|
-
|
|
Dec 20
2024
|
Jon P Stonehouse Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-1.38%
|
-
|
|
Dec 19
2024
|
Helen M. Thackray Chief R&D Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,096
-1.56%
|
$42,672
$7.39 P/Share
|
|
Dec 19
2024
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,950
+24.37%
|
-
|
|
Dec 19
2024
|
Charles K Gayer President and CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.58%
|
$17,227
$7.39 P/Share
|
|
Dec 19
2024
|
Charles K Gayer President and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
125,950
+22.82%
|
-
|
|
Dec 19
2024
|
Anthony Doyle Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.65%
|
$17,227
$7.39 P/Share
|
|
Dec 19
2024
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,700
+24.09%
|
-
|
|
Dec 19
2024
|
Alane P Barnes Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,461
-0.59%
|
$17,227
$7.39 P/Share
|